Peptides News and Research

RSS

Major European medical center includes Critical Diagnostics' Presage ST2 Assay for cardiac care

Critical Diagnostics, a U.S.-based biomarker company focused on cardiovascular diseases, announced today that a major European medical center, Hospital Germans Trias i Pujol in Barcelona Spain, is now using the company's Presage ST2 Assay for routine care and management of their heart failure patients.

2 Jan 2012

Synthetic drugs treat Crohn's disease in mice

A team of Weizmann Institute scientists has turned the tables on an autoimmune disease. In such diseases, including Crohn's and rheumatoid arthritis, the immune system mistakenly attacks the body's tissues. But the scientists managed to trick the immune systems of mice into targeting one of the body's players in autoimmune processes, an enzyme known as MMP9.

26 Dec 2011

Scientists create functional model of native extracellular matrix

Scientists at the National Physical Laboratory (NPL) have created a functional model of the native extracellular matrix that provides structural support to cells to aid growth and proliferation. The model could lead to advances in regenerative medicine.

21 Dec 2011

Hebrew University student wins Kaye Innovation Award for anti-cancer therapy

A strategy for inhibiting a protein that is associated with the spread of cancer has won for a Hebrew University of Jerusalem Ph.D. student in chemistry one of this year's Kaye Innovation Awards at the university.

20 Dec 2011

Acupuncture can reduce protein associated with chronic stress

Acupuncture significantly reduces levels of a protein in rats linked to chronic stress, researchers at Georgetown University Medical Center (GUMC) have found. They say their animal study may help explain the sense of well-being that many people receive from this ancient Chinese therapy.

20 Dec 2011

Atox Bio to advance AB103 Phase 2 study with $3.25M financing

Atox Bio, developer of therapeutics for diseases mediated by an excessive inflammatory response, today announced that it has raised $3.25 million in an initial closing. The investment was co-led by Esperante and a private US-based investor and will be used to advance AB103, currently in phase 2 clinical studies for the treatment of Necrotizing Soft Tissue Infections (NSTI).

19 Dec 2011

Bloomberg TV to air segment on Antigen Express' immunotherapeutic breast cancer vaccine

Generex Biotechnology Corporation today announced that Bloomberg Television is scheduled to air a segment on the immunotherapeutic breast cancer vaccine being developed by its wholly-owned subsidiary, Antigen Express, Inc.

19 Dec 2011

Critical Diagnostics receives FDA clearance for Presage ST2 Assay

Critical Diagnostics, a U.S.-based biomarker company focused on cardiovascular diseases, announced today that the U.S. Food and Drug Administration has cleared the company's Presage ST2 Assay for use as an aid in assessing the prognosis of patients diagnosed with chronic heart failure.

16 Dec 2011

ImmusanT secures $20M in Series A financing

ImmusanT, Inc. announced today it has raised $20 million in Series A financing from Vatera Healthcare Partners LLC to advance development of the biotechnology company's immunotherapeutic vaccine Nexvax2, companion diagnostic and monitoring tool for celiac disease.

14 Dec 2011

Scientists create antigenic myeloma peptide 'cocktail'

Scientists at Dana-Farber Cancer Institute have created a "cocktail" of immune-stimulating peptides they believe could provoke the body's defenses to attack multiple myeloma in its early "smoldering" phase and slow or prevent the blood cancer.

13 Dec 2011

Geron commences GRN1005 Phase 2 trial in breast cancer

Geron Corporation today announced the initiation of GRABM-B (GRN1005 Against Brain Metastases - Breast cancer), a Phase 2 clinical trial to evaluate GRN1005 in patients with brain metastases arising from breast cancer.

13 Dec 2011

New method to design Alzheimer's antibodies

Researchers at Rensselaer Polytechnic Institute have developed a new method to design antibodies aimed at combating disease. The surprisingly simple process was used to make antibodies that neutralize the harmful protein particles that lead to Alzheimer's disease.

12 Dec 2011

Galectin Therapeutics to initiate GM-CT-01 Phase 1/2 combination study in advanced MM

Galectin Therapeutics, the Cancer Centre at the Cliniques universitaires Saint-Luc and the Ludwig Institute for Cancer Research (LICR) announced today that they will initiate a Phase 1/2 safety and efficacy trial testing a novel treatment combination in patients with advanced metastatic melanoma.

9 Dec 2011

Intensive maternal care during infancy promotes effect of NPY in brain

Neuropeptide Y (NPY) is the most abundant peptide hormone of the central nervous system. It is involved in various processes including stress management, the development of anxiety behaviour and body weight regulation. A collaborative research group including scientists from the Max Planck Institute for Medical Research in Heidelberg has demonstrated using mice that intensive maternal care during infancy promotes the effect of NPY in the brain.

8 Dec 2011

INT-777 shows promise against metabolic syndrome

Heart disease is a major cause of death in industrialised countries, and is strongly associated with obesity and diabetes. Many scientists believe that what links these conditions is a chronic, low-grade inflammation.

7 Dec 2011

Unigene acquires exclusive worldwide rights to oral PTH program from GSK

Unigene Laboratories, Inc. today announced that the Company terminated its amended and restated exclusive worldwide license agreement and related development services and clinical supply agreement with GlaxoSmithKline (GSK) pertaining to an oral formulation of a recombinantly produced parathyroid hormone (PTH) analog for the treatment of osteoporosis in postmenopausal women.

5 Dec 2011

HRF inhibitors may provide new therapeutic avenue for treatment of asthma and allergies

La Jolla Institute for Allergy & Immunology scientists have identified the histamine releasing factor (HRF) molecule as a promising target for developing new treatments for a number of allergic reactions including asthma.

3 Dec 2011

Scientists identify 700 anti-bacterial substances from nine species of odorous frogs

Some of the nastiest smelling creatures on Earth have skin that produces the greatest known variety of anti-bacterial substances that hold promise for becoming new weapons in the battle against antibiotic-resistant infections, scientists are reporting.

1 Dec 2011

Neuropharmacology to publish Nutra Pharma's Alpha-Cobratoxin mechanism study on chronic pain

Nutra Pharma Corporation, a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that the journal Neuropharmacology will be publishing a mechanism study on the use of Alpha-Cobratoxin, a component of cobra venom, as a treatment for pain.

1 Dec 2011

Takeda submits alogliptin plus metformin NDA to FDA for treatment of type 2 diabetes

Takeda Pharmaceutical Company Limited (Takeda) announced today that its wholly-owned subsidiary Takeda Global Research & Development Center, Inc., U.S., submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for the fixed-dose combination therapy alogliptin/metformin, which combines alogliptin with metformin in a single tablet.

24 Nov 2011